{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:01:45Z","timestamp":1793142105977,"version":"4.5.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00122","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:26:31Z","timestamp":1585009591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":178,"title":["The Interplay Between Bone and Glucose Metabolism"],"prefix":"10.3389","volume":"11","author":[{"given":"Cristiana","family":"Cipriani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Colangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Santori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Renella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Mastrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/jbmr.2118","article-title":"Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from Scotland","volume":"29","author":"Hothersall","year":"2014","journal-title":"J Bone Miner Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2337\/db16-0063","article-title":"Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes","volume":"65","author":"Sellmeyer","year":"2016","journal-title":"Diabetes."},{"key":"B3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2174\/1574888X10666150531173309","article-title":"Molecular mechanisms of PPAR-gamma governing MSC osteogenic and adipogenic differentiation","volume":"11","author":"Zhuang","year":"2016","journal-title":"Curr Stem Cell Res Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/stem.1659","article-title":"Switch from canonical to non-canonical Wnt signaling mediates high glucose-induced adipogenesis","volume":"32","author":"Keats","year":"2014","journal-title":"Stem Cells."},{"key":"B5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1210\/jc.2012-3634","article-title":"Marrow fat and bone\u2013new perspectives","volume":"98","author":"Fazeli","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/jcp.22291","article-title":"Adipocytes decrease Runx2 expression in osteoblastic cells: roles of PPARgamma and adiponectin","volume":"225","author":"Liu","year":"2010","journal-title":"J Cell Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"R165","DOI":"10.1530\/EJE-18-0182","article-title":"Mechanisms in endocrinology: bone marrow adiposity and bone, a bad romance?","volume":"179","author":"Rharass","year":"2018","journal-title":"Eur J Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s40618-016-0549-y","article-title":"Adipokines and bone metabolism: an interplay to untangle","volume":"39","author":"Pepe","year":"2016","journal-title":"J Endocrinol Invest."},{"key":"B10","first-page":"4","article-title":"Relationship between bone metabolism and adipogenesis","volume":"33","author":"Carnevale","year":"2010","journal-title":"J Endocrinol Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fendo.2019.00524","article-title":"Irisin: a hope in understanding and managing obesity and metabolic syndrome","volume":"10","author":"Arhire","year":"2019","journal-title":"Front Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E844","DOI":"10.3390\/nu10070844","article-title":"Irisin serum levels in metabolic syndrome patients treated with three different diets: a post-hoc analysis from a randomized controlled clinical trial","volume":"10","author":"Osella","year":"2018","journal-title":"Nutrients."},{"key":"B13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.2337\/db13-1106","article-title":"Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling","volume":"63","author":"Zhang","year":"2014","journal-title":"Diabetes."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E530","DOI":"10.1152\/ajpendo.00094.2016","article-title":"Irisin exerts dual effects on browning and adipogenesis of human white adipocytes","volume":"311","author":"Zhang","year":"2016","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"E769","DOI":"10.1210\/jc.2012-2749","article-title":"Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance","volume":"98","author":"Moreno-Navarrete","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0129116","DOI":"10.1371\/journal.pone.0129116","article-title":"The association between metabolic syndrome, bone mineral density, hip bone geometry and fracture risk: the rotterdam study","volume":"10","author":"Muka","year":"2015","journal-title":"PLoS ONE."},{"key":"B17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00223-010-9347-2","article-title":"Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men","volume":"86","author":"Kim","year":"2010","journal-title":"Calcified Tissue Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1148\/radiol.13130375","article-title":"Ectopic and serum lipid levels are positively associated with bone marrow fat in obesity","volume":"269","author":"Bredella","year":"2013","journal-title":"Radiology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.0197-3118.2006.05457.x","article-title":"Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights","volume":"1","author":"McFarlane","year":"2006","journal-title":"J Cardiometab Syndr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.jhh.1001520","article-title":"Bone mass and bone modelling markers in hypertensive postmenopausal women","volume":"17","author":"Perez-Castrillon","year":"2003","journal-title":"J Hum Hypertens."},{"key":"B21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbrc.2015.02.091","article-title":"Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells","volume":"461","author":"Tanaka","year":"2015","journal-title":"Biochem Biophys Res Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/dc14-2989","article-title":"Sclerostin and insulin resistance in prediabetes: evidence of a cross talk between bone and glucose metabolism","volume":"38","author":"Daniele","year":"2015","journal-title":"Diabetes Care."},{"key":"B23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11657-015-0219-2","article-title":"Association and relative importance of multiple obesity measures with bone mineral density: the National Health and Nutrition Examination Survey 2005\u20132006","volume":"10","author":"Yang","year":"2015","journal-title":"Arch Osteoporos."},{"key":"B24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4239\/wjd.v10.i8.421","article-title":"Bone health in diabetes and prediabetes","volume":"10","author":"Costantini","year":"2019","journal-title":"World J Diabet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jbmr.3240","article-title":"Diabetes and deficits in cortical bone density, microarchitecture, and bone size: framingham HR-pQCT study","volume":"33","author":"Samelson","year":"2018","journal-title":"J Bone Miner Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17446651.2019.1575727","article-title":"Understanding and managing secondary osteoporosis","volume":"14","author":"Colangelo","year":"2019","journal-title":"Expert Rev Endocrinol Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00223-003-0023-7","article-title":"Diabetes mellitus: does it affect bone?","volume":"73","author":"Schwartz","year":"2003","journal-title":"Calcified Tissue Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2265.1978.tb02218.x","article-title":"The hypercalciuria of diabetes mellitus: its amelioration with insulin","volume":"9","author":"Raskin","year":"1978","journal-title":"Clin Endocrinol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0168-8227(94)90126-0","article-title":"Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes?","volume":"23","author":"Gregorio","year":"1994","journal-title":"Diabetes Res Clin Pract."},{"key":"B30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00223-016-0210-y","article-title":"Bone-derived factors: a new gateway to regulate glycemia","volume":"100","author":"Bonnet","year":"2017","journal-title":"Calcified Tissue Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"a031666","DOI":"10.1101\/cshperspect.a031666","article-title":"Regulation of energy metabolism by bone-derived hormones","volume":"8","author":"Mera","year":"2018","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fendo.2018.00794","article-title":"Osteocalcin-a versatile bone-derived hormone","volume":"9","author":"Moser","year":"2018","journal-title":"Front Endocrinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e023918","DOI":"10.1136\/bmjopen-2018-023918","article-title":"Relationship between serum osteocalcin\/undercarboxylated osteocalcin and type 2 diabetes: a systematic review\/meta-analysis study protocol","volume":"9","author":"Liu","year":"2019","journal-title":"BMJ Open."},{"key":"B34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1055\/s-0035-1564134","article-title":"Association between serum total osteocalcin level and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"47","author":"Liu","year":"2015","journal-title":"Horm Metab Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0182970","DOI":"10.1371\/journal.pone.0182970","article-title":"Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines","volume":"12","author":"Linossier","year":"2017","journal-title":"PLoS ONE."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0146544","DOI":"10.1371\/journal.pone.0146544","article-title":"Osteoprotegerin regulates pancreatic beta-cell homeostasis upon microbial invasion","volume":"11","author":"Kuroda","year":"2016","journal-title":"PLoS ONE."},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cmet.2015.05.021","article-title":"Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-\u03baB ligand pathway","volume":"22","author":"Kondegowda","year":"2015","journal-title":"Cell Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8724869","DOI":"10.1155\/2017\/8724869","article-title":"Serum osteoprotegerin is a potential biomarker of insulin resistance in chinese postmenopausal women with prediabetes and type 2 diabetes","volume":"2017","author":"Duan","year":"2017","journal-title":"Int J Endocrinol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1097\/GME.0000000000000914","article-title":"Circulating osteoprotegerin in postmenopausal osteoporotic women: marker of impaired glucose regulation or impaired bone metabolism","volume":"24","author":"Mashavi","year":"2017","journal-title":"Menopause."},{"key":"B40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12902-015-0067-5","article-title":"Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study","volume":"15","author":"Niu","year":"2015","journal-title":"BMC Endocr Disord."},{"key":"B41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nm.3084","article-title":"Blockade of receptor activator of nuclear factor-\u03baB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus","volume":"19","author":"Kiechl","year":"2013","journal-title":"Nat Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1210\/jc.2011-2280","article-title":"Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity","volume":"97","author":"Grethen","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-018-0786-9","article-title":"Correlations between serum concentration of three bone-derived factors and obesity and visceral fat accumulation in a cohort of middle aged men and women","volume":"17","author":"Xu","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1515\/jpem-2018-0507","article-title":"The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents","volume":"32","author":"Kutluturk","year":"2019","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/srep00693","article-title":"Importance of \u03b2-Catenin in glucose and energy homeostasis","volume":"2","author":"Elghazi","year":"2012","journal-title":"Sci Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bone.2018.07.021","article-title":"Sclerostin and its association with insulin resistance in children and adolescents","volume":"120","author":"Wedrychowicz","year":"2019","journal-title":"Bone."},{"key":"B48","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.bone.2018.08.007","article-title":"Sclerostin and its significance for children and adolescents with type 1 diabetes mellitus (T1D)","volume":"120","author":"Wedrychowicz","year":"2019","journal-title":"Bone."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.2337\/dc12-1691","article-title":"Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels","volume":"36","author":"Morales-Santana","year":"2013","journal-title":"Diabetes Care."},{"key":"B50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1210\/jc.2011-2186","article-title":"Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus","volume":"97","author":"Garcia-Martin","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1210\/jc.2011-2958","article-title":"Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes","volume":"97","author":"Gennari","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/cen.13300","article-title":"The association between sclerostin and incident type 2 diabetes risk: a cohort study","volume":"86","author":"Yu","year":"2017","journal-title":"Clin Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/jbmr.2341","article-title":"Lipocalin 2: a new mechanoresponding gene regulating bone homeostasis","volume":"30","author":"Rucci","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature21697","article-title":"MC4R-dependent suppression of appetite by bone-derived lipocalin 2","volume":"543","author":"Mosialou","year":"2017","journal-title":"Nature."},{"key":"B55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/iub.1594","article-title":"Lipocalin-2 expression and serum levels as early predictors of type 2 diabetes mellitus in obese women","volume":"69","author":"Rashad","year":"2017","journal-title":"IUBMB Life."},{"key":"B56","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1530\/EJE-11-0660","article-title":"Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study","volume":"165","author":"Liu","year":"2011","journal-title":"Eur J Endocrinol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1055\/s-0030-1265212","article-title":"The lipocalins retinol-binding protein-4, lipocalin-2 and lipocalin-type prostaglandin D2-synthase correlate with markers of inflammatory activity, alcohol intake and blood lipids, but not with insulin sensitivity in metabolically healthy 58-years-old Swedish men","volume":"119","author":"Wallenius","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"B58","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1210\/en.2014-1637","article-title":"Periostin induces pancreatic regeneration","volume":"156","author":"Smid","year":"2015","journal-title":"Endocrinology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"35939","DOI":"10.1074\/jbc.M109.060335","article-title":"The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity","volume":"284","author":"Bonnet","year":"2009","journal-title":"J Biol Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"6423637","DOI":"10.1155\/2016\/6423637","article-title":"Plasma periostin levels are increased in chinese subjects with obesity and type 2 diabetes and are positively correlated with glucose and lipid parameters","volume":"2016","author":"Luo","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B61","doi-asserted-by":"publisher","first-page":"37886","DOI":"10.1038\/srep37886","article-title":"Circulating periostin in relation to insulin resistance and non-alcoholic fatty liver disease among overweight and obese subjects","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1096\/fj.06-6837com","article-title":"BMP-7 functions as a novel hormone to facilitate liver regeneration","volume":"21","author":"Sugimoto","year":"2007","journal-title":"FASEB J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.2337\/db15-0688","article-title":"BMP-7 induces adult human pancreatic exocrine-to-endocrine conversion","volume":"64","author":"Klein","year":"2015","journal-title":"Diabetes."},{"key":"B64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1042\/CS20160543","article-title":"Decreased circulating BMP-9 levels in patients with Type 2 diabetes is a signature of insulin resistance","volume":"131","author":"Luo","year":"2017","journal-title":"Clin Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jdiacomp.2018.04.005","article-title":"The effects of diabetes therapy on bone: a clinical perspective","volume":"32","author":"Kheniser","year":"2018","journal-title":"J Diabetes Complications."},{"key":"B66","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1359\/jbmr.090732","article-title":"Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies","volume":"25","author":"Molinuevo","year":"2010","journal-title":"J Bone Miner Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jdiacomp.2009.05.002","article-title":"Metformin reverses the deleterious effects of high glucose on osteoblast function","volume":"24","author":"Zhen","year":"2010","journal-title":"J Diabetes Complications."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","article-title":"Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk","volume":"48","author":"Vestergaard","year":"2005","journal-title":"Diabetologia."},{"key":"B69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bone.2018.04.004","article-title":"Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes","volume":"112","author":"Stage","year":"2018","journal-title":"Bone."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00198-019-04948-1","article-title":"Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"30","author":"Salari-Moghaddam","year":"2019","journal-title":"Osteoporos Int."},{"key":"B71","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s00774-010-0160-9","article-title":"Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus","volume":"28","author":"Kanazawa","year":"2010","journal-title":"J Bone Miner Metab."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/obr.12885","article-title":"The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: systematic review and meta-analysis of observational studies","volume":"20","author":"Hidayat","year":"2019","journal-title":"Obes Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s00125-017-4269-4","article-title":"Diabetes, bone and glucose-lowering agents: basic biology","volume":"60","author":"Lecka-Czernik","year":"2017","journal-title":"Diabetologia."},{"key":"B74","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.metabol.2009.08.003","article-title":"Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase\/Akt pathway","volume":"59","author":"Ma","year":"2010","journal-title":"Metabolism."},{"key":"B75","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.pharep.2013.12.013","article-title":"Effect of glimepiride on the skeletal system of ovariectomized and non-ovariectomized rats","volume":"66","author":"Fronczek-Sokol","year":"2014","journal-title":"Pharmacol Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4158\/EP15758.OR","article-title":"Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes","volume":"22","author":"Gilbert","year":"2016","journal-title":"Endocr Pract."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2337\/dc17-1525","article-title":"Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride","volume":"41","author":"Kohler","year":"2018","journal-title":"Diabetes Care."},{"key":"B78","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40266-013-0081-0","article-title":"Sulfonylureas and risk of falls and fractures: a systematic review","volume":"30","author":"Lapane","year":"2013","journal-title":"Drugs Aging."},{"key":"B79","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.diabres.2015.05.009","article-title":"Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus","volume":"109","author":"Lapane","year":"2015","journal-title":"Diabetes Res Clin Pract."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00125-014-3289-6","article-title":"Fracture risk in diabetic elderly men: the MrOS study","volume":"57","author":"Napoli","year":"2014","journal-title":"Diabetologia."},{"key":"B81","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00592-018-1101-7","article-title":"Insulin resistance and bone: a biological partnership","volume":"55","author":"Conte","year":"2018","journal-title":"Acta Diabetol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1038\/s41598-017-03748-z","article-title":"Insulin use and excess fracture risk in patients with type 2 diabetes: a propensity-matched cohort analysis","volume":"7","author":"Losada-Grande","year":"2017","journal-title":"Sci Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archinternmed.2009.214","article-title":"Thiazolidinediones and fractures in men and women","volume":"169","author":"Dormuth","year":"2009","journal-title":"Arch Intern Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2265.2010.03784.x","article-title":"Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-years follow-up study","volume":"73","author":"Berberoglu","year":"2010","journal-title":"Clin Endocrinol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1210\/jc.2009-0572","article-title":"Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes","volume":"95","author":"Zinman","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1210\/jc.2012-4018","article-title":"Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus","volume":"98","author":"Bilezikian","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B88","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1753-0407.12833","article-title":"Effect of pioglitazone on bone mineral density in patients with non-alcoholic steatohepatitis: a 36-month clinical trial","volume":"11","author":"Portillo-Sanchez","year":"2019","journal-title":"J Diabetes."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s00198-017-4164-3","article-title":"Impact of pioglitazone on bone mineral density and bone marrow fat content","volume":"28","author":"Pop","year":"2017","journal-title":"Osteoporos Int."},{"key":"B90","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","article-title":"Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice","volume":"81","author":"Pereira","year":"2015","journal-title":"Bone."},{"key":"B91","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.yexcr.2017.09.018","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT), extracellular signal-related kinase (ERK)1\/2, and cAMP\/protein kinase A (PKA) signaling pathways involving beta-catenin","volume":"360","author":"Wu","year":"2017","journal-title":"Exp Cell Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1530\/JOE-17-0278","article-title":"Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"236","author":"Mabilleau","year":"2018","journal-title":"J Endocrinol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","article-title":"Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes","volume":"13","author":"Bunck","year":"2011","journal-title":"Diabetes Obes Metab."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1210\/jc.2015-1176","article-title":"GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women","volume":"100","author":"Iepsen","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B95","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.cgh.2014.09.032","article-title":"Growth trajectories and bone mineral density in anti-tissue transglutaminase antibody-positive children: the Generation R Study","volume":"13","author":"Jansen","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e3168","DOI":"10.1002\/dmrr.3168","article-title":"Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"35","author":"Cheng","year":"2019","journal-title":"Diabetes Metab Res Rev."},{"key":"B97","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1152\/ajpendo.00217.2014","article-title":"DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats","volume":"307","author":"Glorie","year":"2014","journal-title":"Am J Physiol Endocrinol Metab."},{"key":"B98","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00774-014-0581-y","article-title":"Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women","volume":"33","author":"Hegazy","year":"2015","journal-title":"J Bone Miner Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1007\/s00198-017-4051-y","article-title":"Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data","volume":"28","author":"Dombrowski","year":"2017","journal-title":"Osteoporos Int."},{"key":"B100","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/bcp.13167","article-title":"The use of incretins and fractures\u2014a meta-analysis on population-based real life data","volume":"83","author":"Driessen","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fphar.2017.00487","article-title":"Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms","volume":"8","author":"Yang","year":"2017","journal-title":"Front Pharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s13300-019-0668-5","article-title":"Risk of fractures associated with dipeptidyl peptidase-4 inhibitor treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Chen","year":"2019","journal-title":"Diabetes Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B104","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00125-019-4955-5","article-title":"Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS program","volume":"62","author":"Zhou","year":"2019","journal-title":"Diabetologia."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/jbmr.1865","article-title":"Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Bone Miner Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e0123279","DOI":"10.1371\/journal.pone.0123279","article-title":"The use of alendronate is associated with a decreased incidence of type 2 diabetes mellitus\u2013a population-based cohort study in Taiwan","volume":"10","author":"Chan","year":"2015","journal-title":"PLoS ONE."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1210\/jc.2014-3481","article-title":"Bisphosphonates and glucose homeostasis: a population-based, retrospective cohort study","volume":"100","author":"Toulis","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B110","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jdi.12944","article-title":"Alendronate improves fasting plasma glucose and insulin sensitivity, and decreases insulin resistance in prediabetic osteopenic postmenopausal women: a randomized triple-blind clinical trial","volume":"10","author":"Karimi Fard","year":"2019","journal-title":"J Diabetes Investig."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e2991","DOI":"10.1002\/dmrr.2991","article-title":"Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial","volume":"34","author":"Napoli","year":"2018","journal-title":"Diabetes Metab Res Rev."},{"key":"B112","doi-asserted-by":"publisher","first-page":"352858","DOI":"10.1155\/2015\/352858","article-title":"A single 60 mg dose of denosumab might improve hepatic insulin sensitivity in postmenopausal non-diabetic severe osteoporotic women","volume":"2015","author":"Passeri","year":"2015","journal-title":"Int J Endocrinol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00223-015-0075-5","article-title":"Denosumab inhibition of RANKL and insulin resistance in postmenopausal women with osteoporosis","volume":"98","author":"Lasco","year":"2016","journal-title":"Calcified Tissue Int."},{"key":"B114","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1055\/s-2008-1078729","article-title":"Effect of exogenous intermittent recombinant human PTH 1\u201334 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity","volume":"40","author":"Anastasilakis","year":"2008","journal-title":"Horm Metab Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bone.2015.03.018","article-title":"Effect of intermittent PTH treatment on plasma glucose in osteoporosis: a randomized trial","volume":"76","author":"D'Amelio","year":"2015","journal-title":"Bone."},{"key":"B116","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1055\/a-0887-0205","article-title":"Effect of calcium vitamin D co supplementation on insulin, insulin sensitivity, and glycemia: a systematic review and meta-analysis of randomized clinical trials","volume":"51","author":"Asbaghi","year":"2019","journal-title":"Horm Metab Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1900906","article-title":"Vitamin D supplementation and prevention of type 2 diabetes","volume":"381","author":"Pittas","year":"2019","journal-title":"N Engl J Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00198-018-4650-2","article-title":"Diagnosis and management of bone fragility in diabetes: an emerging challenge","volume":"29","author":"Ferrari","year":"2018","journal-title":"Osteoporos Int."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00122\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:26:33Z","timestamp":1585009593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00122\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":118,"alternative-id":["10.3389\/fendo.2020.00122"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00122","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"article-number":"122"}}